News and Announcements
Dealt Limited (ASX: DET) developed Australia’s first real time Commercial Real Estate finance marketplace to assist borrowers to secure non-bank finance
- Published April 08, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
“The dealt.com.au platform was created to provide a platform for developers and investors to access capital for their next project.
We now have over 70 non-bank lenders and family offices looking to fund right across the real estate capital stack.”
James Storey, Founder of Dealt Limited (ASX: DET)
Executive Summary
Dealt Ltd (ASX: DET) is an IPO stage business listing on the ASX in May 2021. Dealt has developed Australia’s first real time Commercial Real Estate finance marketplaces to assist borrowers to secure non-bank finance.
Dealt Group is a diversified business that will specialise in Commercial Real Estate (CRE).
Dealt has been established in response to the emergence of private, non-bank lenders in the $302 billion Australian and New Zealand Commercial Real Estate (CRE) lending market to provide alternative lending sources for borrowers.
Investment Highlights
- Technology-Enabled Real Estate LendingOnline lending platform with scalability including potential future overseas distribution agreements
- Diverse Portfolio of RE LoansDiversified exposure to a portfolio of well-secured, Commercial Real Estate (CRE) senior loans throughout metropolitan Australia and New Zealand
- Diversified Funding SourcesMultiple capital options including warehouse facilities and private debt capital
- Sponsor and Founders Co-Investment360 Capital Group and founders have committed up to 19.0% as co-investment capital
- 15 -Year Real Estate Track Record360 Capital has never lost capital across its real estate lending activities. 360 Capital has transacted over $3 billion across the capital stack.
Investment Offering
Dealt Ltd is looking to undertake a restructure and recapitalisation offer on ASX to raise A$28.4 million via the issue of 56.8 million shares at an offer price of A$0.50 per share.
Click here to register for the Dealt webinar to learn more about the opportunity.
Company Updates
The System’s Immune System: Why Big Tech Will Solve What Big Pharma Can’t
The central investment thesis for the future of human health pits Big Pharma against Big Tech. This blog post explores the “Protocol Paradox” in current cancer care and argues that the convergence of hyperscalers and life-science experts—treating biology as a data and compute problem—represents the defining compounding investment opportunity of this era.
The Life Sciences Supercycle: Why Australian Biotech is Finally Delivering Billion-Dollar Outcomes
Australia’s life sciences sector is experiencing an unprecedented “Supercycle,” finally commercializing world-class research into global, billion-dollar businesses. Learn about the ASX heavyweights, the key drivers (AI, institutional execution, FDA pathway), and the investment opportunity at Emergence 2026.
Following the Billions: Where the Hyperscalers are Betting on the Future
The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.
Backed By Leading Investment Groups and Family Offices
